CPMV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CPMV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Mosaic ImmunoEngineering's current ratio for the quarter that ended in Sep. 2024 was 0.01.
Mosaic ImmunoEngineering has a current ratio of 0.01. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Mosaic ImmunoEngineering has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Mosaic ImmunoEngineering's Current Ratio or its related term are showing as below:
During the past 13 years, Mosaic ImmunoEngineering's highest Current Ratio was 80.71. The lowest was 0.01. And the median was 5.67.
The historical data trend for Mosaic ImmunoEngineering's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mosaic ImmunoEngineering Annual Data | |||||||||||||||||||||
Trend | May14 | May15 | May16 | May17 | May18 | May19 | May20 | Dec21 | Dec22 | Dec23 | |||||||||||
Current Ratio | Get a 7-Day Free Trial | 7.85 | 4.29 | 0.12 | 0.07 | 0.04 |
Mosaic ImmunoEngineering Quarterly Data | ||||||||||||||||||||
Nov19 | Feb20 | May20 | Aug20 | Nov20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Current Ratio | Get a 7-Day Free Trial | 0.06 | 0.04 | 0.02 | - | 0.01 |
For the Biotechnology subindustry, Mosaic ImmunoEngineering's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Mosaic ImmunoEngineering's Current Ratio distribution charts can be found below:
* The bar in red indicates where Mosaic ImmunoEngineering's Current Ratio falls into.
The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.
Mosaic ImmunoEngineering's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Current Ratio (A: Dec. 2023 ) | = | Total Current Assets (A: Dec. 2023 ) | / | Total Current Liabilities (A: Dec. 2023 ) |
= | 0.18 | / | 4.733 | |
= | 0.04 |
Mosaic ImmunoEngineering's Current Ratio for the quarter that ended in Sep. 2024 is calculated as
Current Ratio (Q: Sep. 2024 ) | = | Total Current Assets (Q: Sep. 2024 ) | / | Total Current Liabilities (Q: Sep. 2024 ) |
= | 0.04 | / | 5.301 | |
= | 0.01 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mosaic ImmunoEngineering (OTCPK:CPMV) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Thank you for viewing the detailed overview of Mosaic ImmunoEngineering's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert Baffi | director | C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949 |
Case Western Reserve University | 10 percent owner | 10900 EUCLID AVENUE, CLEVELAND OH 44106 |
Steven W King | director, officer: President and CEO | |
Paul J Lytle | director, officer: EVP, Chief Financial Officer | |
Robert L Garnick | director | C/O PATRIOT SCIENTIFIC, 2038 CORTE DEL NOGAL, SUITE 141, CARLSBAD CA 92011 |
Nicole Franziska Steinmetz | director, officer: Chief Scientific Officer | 871 WILBUR AVENUE, SAN DIEGO CA 92019 |
Dharmesh Mistry | director | 315 PEMBROKE COURT, SAN RAMON CA 94582 |
Carlton M Johnson | director | |
Donald E Schrock | director | C/O INTEGRATED DEVICE TECHNOLOGY, INC., 6024 SILVER CREEK VALLEY ROAD, SAN JOSE CA 95138 |
Paul R Bibeau | officer: VP, Business Development | MICROSEMI CORP, 2381 MORSE AVE, IRVINE CA 92614 |
Frederick C Goerner | officer: Chief Executive Officer | MICROSEMI CORPORATION, ONE ENTERPRISE, ALISO VIEJO CA 92656 |
Clifford L Flowers | officer: Chief Financial Officer | C/O BAKBONE SOFTWARE, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121 |
Harry L Tredennick | director | 6183 PASEO DEL NORTE #180, CARLSBAD CA 92011 |
Thomas J Sweeney | officer: CFO | |
Helmut Jr Falk | director |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 01-19-2021
By ACCESSWIRE ACCESSWIRE • 09-21-2021
By ACCESSWIRE AccessWire • 04-12-2019
By ACCESSWIRE ACCESSWIRE • 12-14-2020
By ACCESSWIRE ACCESSWIRE • 10-12-2021
By [email protected] [email protected] • 12-10-2019
By ACCESSWIRE ACCESSWIRE • 10-01-2021
By ACCESSWIRE ACCESSWIRE • 08-24-2020
By [email protected] [email protected] • 11-05-2019
By ACCESSWIRE ACCESSWIRE • 06-15-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.